The CBER Biologics Effectiveness and Safety (BEST) Initiative #3: Data Sources for Surveillance of Biologics (BEST 3)

The Food and Drug Administration (FDA) Office of Acquisition and Grant Services awarded multiple Indefinite Delivery/Indefinite Quantity (ID/IQ) contracts for the Center for Biologics Evaluation and Research (CBER) Biologics Effectiveness and Safety (BEST) Initiative #3. This initiative, identified by solicitation number FDA-SOL-1224068, focuses on data sources for the surveillance of biologics. Each contract established under this award notice includes an individual ceiling of $50,000,000.00 and a minimum guarantee of $10,000. Performance for these requirements occurs in the USA.

The agency selected three awardees to provide these services. IQVIA Government Solutions, Inc. and Aetna Inc./Healthagen LLC were both issued contracts on September 29, 2020. The Lewin Group, Inc. received its contract award on September 30, 2020. This award notice was published and updated on October 5, 2020, with Suzanne Martella serving as the primary point of contact. There are no attachments associated with this notice.

This procurement is classified under NAICS 518210 for Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services. It also falls under PSC B537 for Special Studies/Analysis- Medical/Health. The individual contract identifiers for the three awardees are 75F40120D00026, 75F40120D00027, and 75F40120D00028.